These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 30629148

  • 41. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.
    Zenklusen I, Jongo S, Abdulla S, Ramadhani K, Lee Sim BK, Cardamone H, Flannery EL, Nguyen T, Fishbaugher M, Steel RWJ, Betz W, Carmago N, Mikolajczak S, Kappe SHI, Hoffman SL, Sack BK, Daubenberger C.
    J Infect Dis; 2018 Apr 23; 217(10):1569-1578. PubMed ID: 29438525
    [Abstract] [Full Text] [Related]

  • 42. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D, Wu Y, McClellan H, Dai W, Rausch K, Jones D, Aebig J, Barnafo E, Butler B, Lambert L, Narum DL, Duffy PE.
    Vaccine; 2017 May 31; 35(24):3232-3238. PubMed ID: 28479180
    [Abstract] [Full Text] [Related]

  • 43. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M, TBVPX-114 study team.
    Lancet Respir Med; 2018 Apr 31; 6(4):287-298. PubMed ID: 29595510
    [Abstract] [Full Text] [Related]

  • 44. Functional and immunological characterization of the var2CSA-DBL5epsilon domain of a placental Plasmodium falciparum isolate.
    Gangnard S, Tuikue Ndam NG, Gnidehou S, Quiviger M, Juillerat A, Faure G, Baron B, Viwami F, Deloron P, Bentley GA.
    Mol Biochem Parasitol; 2010 Oct 31; 173(2):115-22. PubMed ID: 20562018
    [Abstract] [Full Text] [Related]

  • 45. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
    Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG, MSP-1 Malaria Vaccine Working Group.
    Vaccine; 2007 Jan 02; 25(1):176-84. PubMed ID: 16388879
    [Abstract] [Full Text] [Related]

  • 46. Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.
    Stanisic DI, Fink J, Mayer J, Coghill S, Gore L, Liu XQ, El-Deeb I, Rodriguez IB, Powell J, Willemsen NM, De SL, Ho MF, Hoffman SL, Gerrard J, Good MF.
    BMC Med; 2018 Oct 08; 16(1):184. PubMed ID: 30293531
    [Abstract] [Full Text] [Related]

  • 47. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta.
    Fried M, Domingo GJ, Gowda CD, Mutabingwa TK, Duffy PE.
    Exp Parasitol; 2006 May 15; 113(1):36-42. PubMed ID: 16430888
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S.
    PLoS One; 2014 May 15; 9(10):e111020. PubMed ID: 25343487
    [Abstract] [Full Text] [Related]

  • 53. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP.
    Infect Immun; 2005 Jun 15; 73(6):3677-85. PubMed ID: 15908397
    [Abstract] [Full Text] [Related]

  • 54. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE.
    PLoS One; 2016 Jun 15; 11(10):e0163144. PubMed ID: 27749907
    [Abstract] [Full Text] [Related]

  • 55. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
    Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, Zhou H, Aebig J, Dobrescu G, Saul A, Long CA.
    Vaccine; 2006 Mar 24; 24(14):2497-505. PubMed ID: 16434128
    [Abstract] [Full Text] [Related]

  • 56. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.
    Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A.
    Vaccine; 2009 May 18; 27(23):3090-8. PubMed ID: 19428923
    [Abstract] [Full Text] [Related]

  • 57. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults.
    Diemert DJ, Zumer M, Campbell D, Grahek S, Li G, Peng J, Elena Bottazzi M, Hotez P, Bethony J.
    Vaccine; 2022 Oct 06; 40(42):6084-6092. PubMed ID: 36114129
    [Abstract] [Full Text] [Related]

  • 58. Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development.
    Chêne A, Gangnard S, Dechavanne C, Dechavanne S, Srivastava A, Tétard M, Hundt S, Leroy O, Havelange N, Viebig NK, Gamain B.
    NPJ Vaccines; 2018 Oct 06; 3():28. PubMed ID: 30038803
    [Abstract] [Full Text] [Related]

  • 59. Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.
    Blank A, Fürle K, Jäschke A, Mikus G, Lehmann M, Hüsing J, Heiss K, Giese T, Carter D, Böhnlein E, Lanzer M, Haefeli WE, Bujard H.
    NPJ Vaccines; 2020 Oct 06; 5(1):10. PubMed ID: 32025341
    [Abstract] [Full Text] [Related]

  • 60. Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial.
    Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, Uppal G, Jena R, Rawat A, Kumar P, Bhardwaj R, Yazdani SS, Hans D, Mehta S, Srinivasan A, Anil K, Madhusudhan RL, Patel J, Singh A, Rao R, Gangireddy S, Patil R, Kaviraj S, Singh S, Carter D, Reed S, Kaslow DC, Birkett A, Chauhan VS, Chitnis CE.
    NPJ Vaccines; 2018 Oct 06; 3():48. PubMed ID: 30302285
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.